Global Anti-CD20 Monoclonal Antibodies Market Research Report 2022
Anti-CD20 monoclonal antibody is an anti-tumor agent for the treatment of non-hodge B cell malignancy.Unlike conventional treatments, these antibodies attack the CD20 antigen on cancer cells.
Due to the COVID-19 pandemic, the global Anti-CD20 Monoclonal Antibodies market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Anti-CD20 Monoclonal Antibodies market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Anti-CD20 Monoclonal Antibodies landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
First Generation Anti-CD20 Monoclonal Antibody accounting for % of the Anti-CD20 Monoclonal Antibodies global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Oncology segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Anti-CD20 Monoclonal Antibodies include Genmab, Amgen, Celltrion, Roche, Novartis AG, Pfizer, Biogen, Genentech and Immunomedics, etc. In terms of revenue, the global 3 largest players have a % market share of Anti-CD20 Monoclonal Antibodies in 2021.
This report focuses on Anti-CD20 Monoclonal Antibodies volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Anti-CD20 Monoclonal Antibodies market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Anti-CD20 Monoclonal Antibodies Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
First Generation Anti-CD20 Monoclonal Antibody
Second Generation Anti-CD20 Monoclonal Antibody
Third Generation Anti-CD20 Monoclonal Antibody
Segment by Application
Oncology
Neurology
Immunology
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Genmab
Amgen
Celltrion
Roche
Novartis AG
Pfizer
Biogen
Genentech
Immunomedics
Spectrum Pharmaceuticals
Bio-Rad Laboratories
LFB Biotechnologie
Due to the COVID-19 pandemic, the global Anti-CD20 Monoclonal Antibodies market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Anti-CD20 Monoclonal Antibodies market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Anti-CD20 Monoclonal Antibodies landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
First Generation Anti-CD20 Monoclonal Antibody accounting for % of the Anti-CD20 Monoclonal Antibodies global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Oncology segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Anti-CD20 Monoclonal Antibodies include Genmab, Amgen, Celltrion, Roche, Novartis AG, Pfizer, Biogen, Genentech and Immunomedics, etc. In terms of revenue, the global 3 largest players have a % market share of Anti-CD20 Monoclonal Antibodies in 2021.
This report focuses on Anti-CD20 Monoclonal Antibodies volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Anti-CD20 Monoclonal Antibodies market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Anti-CD20 Monoclonal Antibodies Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
First Generation Anti-CD20 Monoclonal Antibody
Second Generation Anti-CD20 Monoclonal Antibody
Third Generation Anti-CD20 Monoclonal Antibody
Segment by Application
Oncology
Neurology
Immunology
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Genmab
Amgen
Celltrion
Roche
Novartis AG
Pfizer
Biogen
Genentech
Immunomedics
Spectrum Pharmaceuticals
Bio-Rad Laboratories
LFB Biotechnologie
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
